

ЎЗБЕКИСТОН РЕСПУБЛИКАСИ СОҒЛИҚНИ САҚЛАШ ВАЗИРЛИГИ
ТОШКЕНТ ТИББИЁТ АКАДЕМИЯСИ

2024 №5

2011 йилдан чиқа бошлаган

TOSHKENT TIBBIYOT AKADEMIYASI
АХБОРОТНОМАСИ



В Е С Т Н И К

ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ

Тошкент



Выпуск набран и сверстан на компьютерном издательском комплексе

редакционно-издательского отдела Ташкентской медицинской академии

Начальник отдела: М. Н. Аслонов

Редактор русского текста: О.А. Козлова

Редактор узбекского текста: М.Г. Файзиева

Редактор английского текста: А.Х. Жураев

Компьютерная корректура: З.Т. Алюшева

Учредитель: Ташкентская медицинская академия

Издание зарегистрировано в Ташкентском Городском управлении печати и информации

Регистрационное свидетельство 02-00128

Журнал внесен в список, утвержденный приказом № 201/3 от 30 декабря 2013года

реестром ВАК в раздел медицинских наук

Рукописи, оформленные в соответствии

с прилагаемыми правилами, просим направлять

по адресу: 100109, Ташкент, ул. Фароби, 2,

Главный учебный корпус ТМА,

4-й этаж, комната 444.

Контактный телефон: 214 90 64

e-mail: rio-tma@mail.ru

rio@tma.uz

Формат 60x84 1/8. Усл. печ. л. 9,75.

Гарнитура «Cambria».

Тираж 150.

Цена договорная.

Отпечатано на ризографе редакционно-издательского отдела ТМА.

100109, Ташкент, ул. Фароби, 2.

Вестник ТМА №5, 2024
РЕДАКЦИОННАЯ КОЛЛЕГИЯ

Главный редактор

проф. А.К. Шадманов

Заместитель главного редактора

проф. О.Р.Тешаев

Ответственный секретарь

проф. Ф.Х.Иноятова

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ

акад. Аляви А.Л.

проф. Билалов Э.Н.

проф. Гадаев А.Г.

проф. Жае Вук Чои (Корея)

акад. Каримов Ш.И.

проф. Татьяна Силина (Украина)

акад. Курбанов Р.Д.

проф. Людмила Зуева (Россия)

проф. Метин Онерчи (Турция)

проф. Ми Юн (Корея)

акад. Назыров Ф.Г.

проф. Нажмутдинова Д.К.

проф. Саломова Ф.И.

проф. Саша Трескач (Германия)

проф. Шайхова Г.И.

Члены редакционного совета

проф. Акилов Ф.О. (Ташкент)

проф. Аллаева М.Д. (Ташкент)

проф. Хамдамов Б.З. (Бухара)

проф. Ирискулов Б.У. (Ташкент)

проф. Каримов М.Ш. (Ташкент)

проф. Маматкулов Б.М. (Ташкент)

проф. Охунов А.О. (Ташкент)

проф. Парпиева Н.Н. (Ташкент)

проф. Рахимбаева Г.С. (Ташкент)

проф. Хамраев А.А. (Ташкент)

проф. Холматова Б.Т. (Ташкент)

проф. Шагазатова Б.Х. (Ташкент)

<i>Abdurazzakova D.S., Matchanov S.X. REVMATOIDLI ARTRITDA GOLIMUMAB BILAN OLIB BORILGAN KOMPLEKS TERAPIYANING BO'G'IM DESTRUKSIYASIGA TA'SIRINI O'RGANISH</i>	<i>Abdurazzakova D.S., Matchanov S.X. STUDY OF THE EFFECT OF COMPLEX THERAPY WITH GOLIMUMAB IN RHEUMATOID ARTHRITIS ON ARTICULAR DESTRUCTION</i>	58
<i>Agzamova G.S., Jo'raboyeva G.B. REVMATOID ARTRITDA BUYRAK ZARLANISHINING O'ZIGA XOS XUSUSIYATLARI</i>	<i>Agzamova G.S., Zhuraboeva G.B. FEATURES OF KIDNEY DAMAGE IN RHEUMATOID ARTHRITIS</i>	61
<i>Bekenova G.T., Axmedova N.A., Ganiyeva N.A., Asqarov N.L., Tolipov U.U., Alimova N.Z., Hasanova Sh.A. IMPORTANCE OF PULSE-THERAPY IN PERIPHERAL VASCULAR DAMAGE IN SYSTEMIC SCLERODERMA</i>	<i>Бекенова Г.Т., Ахмедова Н.А., Ганиева Н.А., Аскарров Н.Л., Толипов У.У., Алимова Н.З., Хасанова Ш.А. ЗНАЧЕНИЕ ПУЛЬС-ТЕРАПИИ ПРИ ПОРАЖЕНИИ ПЕРИФЕРИЧЕСКИХ СОСУДОВ ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ</i>	67
<i>Bekenova G.T., Axmedova N.A., G'aniyeva N.A., Asqarov N.L., Tolipov O'U., Alimova N.Z., Xasanova Sh.A. TIZIMLI SKLERODERMİYADA PERIFERIK TOMIRLAR ZARARLANISHIDA PULS-TERAPIYANING AHAMIYATI</i>	<i>Бердиева Д.У., Ризамухамедова М.З., Нурмухамедова Н.С. ПОЛИАНГИИТЛИ ГРАНУЛЕМАТОЗНИНГ КЛИНИК КЕЧИШИННИНГ ЎЗИГА ҲОС ХУСУСИЯТЛАРИ</i>	70
<i>Бобоев К.Т., Мусашайхова Ш.М., Джумабаева С.Э. КЛИНИЧЕСКИЕ И ЛАБОРАТОРНЫЕ ПОКАЗАТЕЛИ ПРИ ОСТРОМ МИЕЛОИДНОМ ЛЕЙКОЗЕ</i>	<i>Boboev K.T., Musashaykhova Sh.M., Djumabayeva S.E. CHARACTERISTICS OF CLINICAL AND LABORATORY PARAMETERS OF ACUTE MYELOID LEUKEMIA</i>	77
<i>Ганиева Н.А., Ризамухамедова М.З., Бекенова Г.Т. ТИЗИМЛИ СКЛЕРОДЕРМИЯЛИ БЕМОРЛАРДА ЭРТА АТЕРОСКЛЕРОЗНИНГ ХАВФ ОМИЛЛАРИ ВА ЯЛЛИФЛАНИШ МЕДИАТОРЛАРИНИНГ ЎЗARO МУНОСАБАТИНИ БАҲОЛАШ</i>	<i>Ganiyeva N.A., Rizamukhamedova M.Z., Bekenova G.T. EVALUATION OF FACTORS RELATED TO THE RISK OF EARLY ATHEROSCLEROSIS AND MEDIATORS OF INFLAMMATION AND SYSTEMIC SCLERODERMA</i>	80
<i>Daurenbekova A.Sh., Djurayeva E.R. QO'L PANJA BO'G'IMLARI OSTEOARTROZI: DIAGNOSTIKASI VA HAYOT SIFATINI BAHOLASH</i>	<i>Daurenbekova A.Sh., Djuraeva E.R. OSTEOARTHRITIS OF THE HAND JOINTS: DIAGNOSTICS AND ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS</i>	84
<i>Djurayeva E.R. PODAGRA KASALLIGIDA GIPOURIKEMIK DAVOGA ZAMONAVIY YONDOSHUV</i>	<i>Djuraeva E.R. MODERN APPROACHES TO HYPOURICEMIC THERAPY FOR GOUT</i>	87
<i>Zakirhodzhaev R.A., Saginova J.T., Bazarbaeva A.T. EFFECTIVE METHODS FOR TREATMENT OF DRY EYE SYNDROME IN SYSTEMIC DISEASES</i>	<i>Zakirhodjaev R.A., Saginova J.T., Bazarboeva A.T. TIZIMLI KASALLIKLARDA QURUQ KO'Z SINDROMINI DAVOLASHNING SAMARALI USULLARI</i>	90
<i>Ziyaeva F.K., Djuraeva E.R., Ganiyeva N.A. CHARACTERISTICAL TRAITS OF THE CLINIC AND DIAGNOSIS OF RHEUMATOID ARTHRITIS IN EARLY STAGES</i>	<i>Ziyayeva F.K., Djo'rayeva E.R., G'aniyeva N.A. ERTA BOSQICHLARDA REVMATOID ARTRITNING KLINIKASI VA DIAGNOSTIKASI XUSUSIYATLARI</i>	92
<i>Ильхамова К.А., Курбанов Б.Б., Курбанов Д.Д. ИЗУЧЕНИЕ ПАТОГЕНЕТИЧЕСКОЙ РОЛИ ГЕНА РЕГУЛЯТОРА ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В РАЗВИТИИ ПРЕЭКЛАМПСИИ</i>	<i>Ilkhamova K.A., Kurbanov B.B., Kurbanov D.D. STUDYING THE PATHOGENETIC ROLE OF THE ENDOTHELIAL DYSFUNCTION REGULATOR GENE IN THE DEVELOPMENT OF PRE-ECLAMPSIA</i>	96
<i>Исакова М.Б., Исраилов А.А., Самадова Д.О., Исмаилова З.Ш. РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ ИНЪЕКЦИОННЫМИ ФОРМАМИ МЕТОТРЕКСАТА В ДОЗЕ 15 МГ БОЛЬНЫХ С РАННИМ ПСОРИАТИЧЕСКИМ АРТРИТОМ</i>	<i>Isakova M.B., Israilov A.A., Samadova D.O., Ismailova Z.Sh. RESULTS OF USING INJECTABLE FORMS OF METHOTREXATE AT A DOSE OF 15 MG IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS</i>	99
<i>Мамасаидов А.Т., Мамасаидов Ф.А. ОЦЕНКА СПОНТАННОЙ ПРОЛИФЕРАТИВНОЙ АКТИВНОСТИ В-ЛИМФОЦИТОВ ПРИ ЛЮПУС-ГЕПАТИТЕ</i>	<i>Mamasaidov A.T., Mamasaidov F.A. ASSESSMENT OF SPONTANEOUS PROLIFERATIVE ACTIVITY OF B-LYMPHOCYTES IN LUPUS HEPATITIS</i>	101
<i>Махмудова М.С., Зубайдуллаева М.Т., Шукурджанова С.М., Шоалимова З.М. ОЦЕНКА ЭФФЕКТИВНОСТИ ПРИМЕНЕНИЯ ХОНДРОПРОТЕКТОРОВ В ЛЕЧЕНИИ ОСТЕОАРТРИТА</i>	<i>Makhmudova M.S., Zubaidullaeva M.T., Shukurdzhanova S.M., Shoalimova Z.M. EVALUATION OF THE EFFECTIVENESS OF THE USE OF CHONDROPROTECTORS IN THE TREATMENT OF OSTEOARTHRITIS</i>	104
<i>Makhmudova M.S., Nuritdinova N.B., Yarmukhamedova D.Z. ULTRASOUND EXAMINATION IN THE DIAGNOSIS OF OSTEOARTHRITIS</i>	<i>Maxmudova M.S., Nuritdinova N.B., Yarmuxamedova D.Z. OSTEOARTRIT TASHXISIDA ULTRATOVUSH TEKSHIRUVI</i>	107
<i>Mirzajonova G. S., PulatovaSh. B. ANKILOZLOVCHI SPONDILOARTRITDA YURAK ZARARLANISHI</i>	<i>Mirzadzhonova G.S., Pulatova Sh.B. DAMAGES OF HEART IN ANKYLOSING SPONDYLOARTHRITIS</i>	111

CHARACTERISTICAL TRAITS OF THE CLINIC AND DIAGNOSIS OF RHEUMATOID ARTHRITIS IN EARLY STAGES

Ziyayeva F.K., Djuraeva E.R., Ganieva N.A.

ОСОБЕННОСТИ КЛИНИКИ И ДИАГНОСТИКИ РЕВМАТОИДНОГО АРТРИТА НА РАННИХ СТАДИЯХ

Зияева Ф.К., Джуряева Э.Р., Ганиева Н.А.

ERTA BOSQICHLARDA REVMATOID ARTRITNING KLINIKASI VA DIAGNOSTIKASI XUSUSIYATLARI

Ziyayeva F.K., Djo'rayeva E.R., G'aniyeva N.A.

Tashkent Medical Academy

Цель: изучение клинических особенностей и диагностической значимости белка 14-3-3η в крови больных на ранних стадиях заболевания. **Материал и методы:** в исследование включены 68 больных ревматоидным артритом в возрасте от 19 до 74 лет (средний возраст 44,2±3,2 года) с давностью заболевания до 1-го года (от 6 до 52 нед). **Результаты:** дебют ревматоидного артрита наблюдается преимущественно в среднем возрасте. Среди форм артритов лидирует полиартрит с одновременным поражением мелких и крупных суставов. У больных на ранней стадии ревматоидного артрита диагностировали II ФК суставной недостаточности. На ранней стадии РА серонегативность была более выражена. **Выводы:** у больных ревматоидным артритом на ранних стадиях 14-3-3η белок в крови определяется значительно чаще, чем АЦЦП и ревматоидный фактор, что указывает на высокую значимость этого иммунологического метода для диагностики раннего ревматоидного артрита.

Ключевые слова: ранний ревматоидный артрит, суставной синдром, клиника, диагностика, антициклический пептид цитруллина, белок 14-3-3η.

Maqsad: kasallikning dastlabki bosqichida bemorlar qonidagi 14-3-3η oqsilining klinik belgilari va diagnostik ahamiyatini o'rganish. **Material va usullar:** tadqiqotga 19 yoshdan 74 yoshgacha bo'lgan (o'rtacha yoshi 44,2±3,2 yil) 1 yilgacha (6 dan 52 haftagacha) davom etadigan revmatoid artritli 68 bemor ishtirok etdi. **Natijalar:** revmatoid artritning boshlanishi asosan o'rta yoshda kuzatiladi. Artrit shakllari orasida etakchi o'rinni kichik va katta bo'g'imlarga bir vaqtning o'zida zarar etkazadigan poliartrit hisoblanadi. Revmatoid artritning dastlabki bosqichidagi bemorlarga FC II artikulyar etishmovchilik tashxisi qo'yilgan. RA ning dastlabki bosqichida seronegativlik aniqroq edi. **Xulosa:** erta bosqichlarda revmatoid artrit bilan og'riqan bemorlarda qonda 14-3-3η protein ACCP va revmatoid omilga qaraganda sezilarli darajada tez-tez aniqlanadi, bu erta revmatoid artrit tashxisi uchun ushbu immunologik usulning yuqori ahamiyatini ko'rsatadi.

Kalit so'zlar: erta revmatoid artrit, artikulyar sindrom, klinik ko'rinish, tashxis, antisiklik sitrulin peptid, protein 14-3-3η.

Representing one of the rheumatological diseases occurring with articular syndrome, rheumatoid arthritis (RA) is characterized by damage to functionally important joints, which leads to disability of patients, especially among young and middle-aged people, which determine the social significance and urgency of the problem. It was found that about 70% of cases of erosive and destructive changes in the joints develop during the first 3-6 months from the onset of the disease, which determines the unfavorable prognosis of its course [4].

Currently, the concept of early stage of RA is interpreted ambiguously. Various authors define it as periods of time from several months to several years. Some experts identify the first 3 months of the disease as a very early stage. Scientific research, which is carried out in the framework of the problem of early arthritis, is devoted primarily to the solution of two closely related issues. Firstly, the possibilities of establishing a reliable diagnosis are being studied, and secondly, approaches to prescribing the optimal therapy option for a given period of the disease are being worked out [1].

The problem of accurate early diagnosis of RA, which is inextricably linked with the study of the immediate and distant outcomes of the disease, is currently especially relevant, in connection with the possibility of slowing down the development of the disease with the help of modern methods of treatment, if therapy is started early [3]. It is now widely accepted that early identification of RA, assessment of disease severity at diagnosis, and implementation of an effective treatment strategy can significantly improve patient prognosis. Recognizing this, in 2010, criteria for the classification of RA were established, aimed at defining the disease by its early signs. Although the diagnosis of RA is made mainly on the basis of clinical data, an immunological examination plays a significant role in the diagnosis of this disease, which makes it possible to establish the inflammatory activity of the process, as well as to detect a wide range of serological markers. The detection of autoantibodies in RA not only allows to confirm the diagnosis in case of an unclear clinical picture, but is also one of the methods for determining the prognosis of the disease. Effective treatment of RA depends on early identification,

followed by timely invention and proper monitoring of treatment responses, which remain challenges for rheumatologists due to the lack of biomarkers of high sensitivity and specificity. Seronegativity in both early and steady-state RA remains the main obstacle for both ACCP and RF, which underlines the need for new additional markers that will improve diagnostic sensitivity [5,6]. It is necessary to develop new markers for RA so that patients can be correctly classified into different risk groups. Current markers only estimate about thirty percent of the total diversity in predicting disease outcome [2]. Protein 14-3-3 η is a new biomarker for the detection of PA [7]. There are seven forms of the 14-3-3 family of intracellular proteins. They have about 50% amino acid similarity to each other and interact with a variety of intracellular proteins, thereby controlling many biological processes, including protein synthesis, cellular metabolism, protein transport, and cytoskeleton transport [8]. In general, isomers, only 14-3-3 η were present in synovial fluid with high levels (at least 5 times higher than their corresponding sera), suggesting that the joint is a likely source of 14-3-3 η [9, ten]. In the extracellular environment, soluble 14-3-3 η has ligand activity, preferentially activating cells of the innate immune system [10]. Soluble 14-3-3 η acts through signaling cascades as extracellular kinase and the P38 pathway, which leads to upregulation of some pro-inflammatory cytokines such as interleukin 6 (IL-6), tumor necrosis factor- α (TNF- α), interleukin 1 β (IL-1 β), matrix metalloproteinase 9 (MMP-9) and activator of the nuclear factor- κ B ligand receptor (RANKL) [7]. Serum 14-3-3 levels may be high in patients with RA but not in other conditions such as osteoarthritis, osteoporosis, gout, psoriasis, Crohn's disease, ulcerative colitis, type 1 diabetes, systemic lupus erythematosus, primary Sjogren's syndrome, scleroderma and multiple sclerosis [8,9]. Early diagnosis of RA can minimize irreversible joint damage [1]. In addition, elevated serum 14-3-3 η

protein levels were associated with more severe joint erosion and poorer treatment outcomes. Here, we have summarized new knowledge about the role played by 14-3-3 η in RA and its clinical implications as a surrogate for diagnostic, prognostic and therapeutic responses, as well as a potential drug target for RA.

Purpose of the research

To study clinical features and diagnostic significance of 14-3-3 η protein in the blood of patients at the early stages of disease.

Material and methods

The study included 68 patients with RA (meeting the EULAR/ACR criteria, 2010) aged 19 to 74 years (mean age 44.2 \pm 3.2 years) with a disease duration of up to 1 year (from 6 to 52 weeks), who underwent inpatient treatment in the departments of cardio-rheumatology, rheumatology and were registered in the arthrology department of multidisciplinary clinic of TMA for the period 2019-2020. By sex, the patients were distributed as follows: 63 women (93%) and 5 men (7%) (F:M=12:1). The average duration of the disease was 8.6 \pm 0.7 months (Table).

To determine RA activity, the following indicators were used: the severity of pain in joints, assessed by the patient on a visual analogue scale (VAS), the total activity of the disease was assessed according to the recommended EULAR index DAS28 and ESR (mm/h) according to Westergren with the release of 3 main degrees and CRP in serum blood. To assess the functional capabilities of the patient, the definition of the functional class was used. The functional status of the patient was determined by the Stanford Health Assessment Questionnaire (HAQ, 1980) and Richie. Laboratory examination included general clinical and biochemical blood tests. Diagnostics of autoantibody panels included quantitative determination of RF by the Waaler-Rose method, as well as ACCP and 14-3-3 η protein by enzyme-linked immunosorbent assay.

Table

Clinical characteristics of patients with RA, n=68

Groups	Gender, abs. (%)		Average age	Average duration of the disease (in months)
	Man	Woman		
1, n=16	2 (12,5)	14 (87,5)	44,5 \pm 2,8	4,6 \pm 0,8
2, n=17	1 (5,9)	16 (94,1)	50,4 \pm 2,8	5,5 \pm 0,9
3, n=16	-	16 (100)	38,1 \pm 3,3	5,9 \pm 0,9
4, n=19	2 (10,5)	17 (89,5)	43,8 \pm 3,7	7,0 \pm 0,9

Statistical analysis of the results was carried out using Microsoft Excel (2007). To describe the distribution of the analyzed indicators, the frequency of occurrence for discrete variables or parameters for continuous ones were calculated using the standard representation $M\pm m$, where M is the arithmetic mean, am is the statistical error of its determination (standard deviation of the group mean), as well as other parameters, including percentiles.

Results and Discussions

Patients with a course of RA less than 3 months accounted for 18.7% in Group 1, 29.4% in Group 2, 18.8%

in Group 3, and 21% in Group 4. Disease duration up to 6 months in group 1 was found in 56.3% of patients, in 2 - in 29.4% of patients, in 3 - 31.2% and in 10.7% of patients in group 4. The 12-month prescription of the disease was determined in group 1 in 12.5% of patients, in group 2 - in 23.6%, in group 3 - in 25%, and in group 4 - in 36.8% of patients.

The average value of morning stiffness in all examined patients was 79.1 \pm 19.3 minutes. The duration of morning stiffness in patients of group 1 averaged 46.6 \pm 15.8 minutes, in patients 2 - 75.6 \pm 27.3 minutes,

in patients in groups 3 and 4 it averaged 65.6 ± 19.7 and 128.4 ± 14.5 minutes, respectively, regardless of the duration of the disease. Analysis of the nature of the articular syndrome in patients with RA showed that polyarthrititis, as a criterion for RA, was detected in 57.4% of patients, the mono-oligo-articular nature of joint damage was detected in 42.6% of those examined.

The data presented indicate the highest percentage (72%) of hand joints lesions in RA patients, regardless of the duration of its course. In the onset of RA, the pathological process more often involved the joints of the hands (72%), less often - the knee (13.2%), foot joints (2.8%), shoulder (1.5%), elbow (2.9%) and ankle joints (7.6%). Only in 9 patients (13.2%), there was a simultaneous lesion of almost all joints.

The analysis of the degree of activity according to DAS28 showed that in 23.5% of patients in group 4, the average value was 5.31 ± 0.49 , which corresponded to the 3 degree of activity, in 76.5% of patients, on average, 4.8 ± 0.1 (II degree of activity). There were no patients with a low degree of RA activity.

The average score of the HAQ index in the examined patients was 1.05 ± 0.03 and this was assessed as moderate functional disorders of the joints. The minimum functional impairment of the joints was observed in patients of group 1 (0.99 ± 0.03). In the remaining groups, there was an average degree of functional disorders of the joints according to the HAQ index (1.07 ± 0.03).

The maximum indicator according to the Ritchie index, which includes the number of painful and swollen joints, was recorded in patients of group 4 (26.6 ± 0.8), the minimum - in patients of group 1 (15.6 ± 0.3). The average score of the Ritchie index in the examined patients was 21.1 ± 0.4 . The severity of joint pain according to the VAS showed the highest numbers (77.4 ± 2.1) (severe pain) in patients of group 4, when the lowest score was reached by patients in group 1 (49.4 ± 2.8) (moderate pain). The average VAS scores in patients of groups II and III were practically the same, which corresponded to 70 ± 2 and 70.6 ± 2.3 (severe pain).

Among the examined patients, FC II was found in 40%, FC I - in 34%, FC III was established in 26% of patients. It should be noted that 74% of patients in group IV had a higher FC, namely FC III. In 81% of patients in group I, FC I was noted.

Seroprevalence is of no small importance in the diagnosis of RA. According to the results of this study, seronegativity was mostly observed in the early stage of RA. According to the literature, it is known that patients who are positive for the RF have a worse prognosis for the course of the disease. However, the RF phenotype has two significant limitations. First, the specificity of this test for RA is rather low: RF is found in about 5% of healthy people, in 5-25% of elderly people, as well as in a significant number of patients with chronic diseases. Secondly, the presence of RF is not stable. The frequency of RF detection depends significantly on the duration of the disease. The results of one of the domestic studies showed that in the first 6 months it is detected only in 15-43% of patients with RA, subsequently, some RF-negative patients become

RF-positive. Under the influence of treatment, the reverse transformation is also possible [6].

With a disease duration of up to one year, 43% of patients were seropositive in the RF, and 57% were seronegative. In the group of patients with RA duration of less than 3 months, RF was detected in 27%, and with an increase in the duration of the disease, its indicator increased to 62%. ACCP was determined in 80% of the examined patients with a disease duration of up to 3 months, by 12 months of illness, on average, in 90.6% of patients, this indicator turned out to be positive 14-3-3 η protein was determined in all (100%) examined patients, regardless of the duration of the disease. The results of the study indicate that seropositivity of RA is unstable, an increase in the frequency of detection of RF was recorded in patients with a long duration of the disease, and it should be noted that during therapy, the RF titer may decrease or not even be determined [2,4].

According to the literature, it was found that ACCP is more specific for RA and at least as sensitive as traditional RF: the sensitivity of ACCP in the diagnosis of RA is 70-80%, specificity - 98-99%. The sensitivity of the test for patients with early RA ranges between 40 and 70% [7]. In our study, during the initial examination, ACCP was detected to a greater extent than RF in RA patients (86%). At the same time, the 14-3-3 η protein was detected in all patients with RA, in comparison with RF and ACCP.

A direct correlation was established between the duration of the disease and the frequency of detection of ACCP, while in patients the correlation between the duration of the disease and the frequency of detection of the 14-3-3 η protein was not established. In patients with long periods of disease duration (7.0 ± 0.9 months), high diagnostic titers of ACCP were revealed (47.1 ± 6.1), in contrast to other groups. A 14-3-3 η protein was determined in all patients regardless of the duration of the disease. This indicates that with an increase in the duration of the disease, the diagnostically significant ACCP figures increase. It should be noted that 80% of patients with a disease duration of up to 3 months were seropositive for ACCP, 100% for 14-3-3 η protein, while the percentage of RF detection in these patients was only 31.2%. By 12 months of illness, the detection of ACCP increased to 90.6%, RF to 37.5%, and the initial results of 14-3-3 η protein did not change (100%). Thus, the determination of the 14-3-3 η protein was significantly superior in sensitivity to ACCP and RF.

Conclusion

1. The debut of RA is observed mainly in middle age. Among the forms of arthritis, polyarthrititis is leading with simultaneous damage to small and large joints. The metacarpophalangeal joints are more often involved in the pathological process. In the onset of RA, the mono-oligo-articular nature of the articular syndrome, the defeat of the first metacarpophalangeal joint and the asymmetric damage to the joints are noted.

2. The average duration of morning stiffness continued with an increase in the duration of the disease.

3. Patients with RA onset had II degree of activity according to DAS28. The average score of the HAQ index in the examined patients was 1.05 ± 0.03 and this was assessed as moderate functional disorders of the joints.

The maximum indicator according to the Ritchie index, which includes the number of painful and swollen joints, was recorded in patients with a high degree of disease activity. Patients at an early stage of RA were diagnosed with FC II of joint insufficiency.

4. At an early stage of RA, seronegativity was more marked.

5. In patients with RA in the early stages of 14-3-3 η, the protein in the blood is determined much more often than ACCP and RF, which indicates the high importance of this immunological method for the diagnosis of early RA.

References

1. American Intercollegiate of rheumatologists. Recommendations for use of basic anti-inflammation preparations and Biologic agents in rheumatoid arthritis // Clin. Pharmacol. Ther. – 2018. – Vol. 18, №1. – P. 43

2. Aripova N.A., Nabieva D.A., Djuraeva E.R., Ganieva N.A. Clinical and prognostic characteristics of “disease-specific” autoantibodies insystemic scleroderma // Asian J. Med. Princ. Clin. Pract. – 2021. – Vol. 13, №4. – P. 26-38.

3. Berdiyeva D.U., Djurayeva E.R., Sultonova M.X. et al. Evaluation of the effectiveness of target therapy in the treatment of patients with polyangiitis granulomatosis // J. Hun. Univer. (Nat. Sci.) – 2023. – Vol. 50, №07. – P. 104-115.

4. Bijlsma J.W., Wcinblatt M.E. Optimal use of the methotrexate: the advantages of tight control // Ann. Reum. Dis. – 2017. – Vol. 32. – P. 11.

5. Calguneri M., Pay S., Caliskaner Z. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis // Clin. Exp. Rheumatol. – 2019. – Vol. 17. – P. 699-704.

6. Cohen S.B., Emery P.A., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty four weeks. // Arthritis Rheum. – 2016. – Vol. 9, №4. – P. 2793-2806.

7. Duer-Jensenc A.H., Stewart N.O., Crabbe J.N. Magnetic resonance imaging of the wrist in early rheumatoid arthritis re-

veals a high prevalence of erosions at four months after symptom onset // Ann. Rheum. Dis. – 2016. – Vol. 6, №7. – P. 350.

8. Mukhammadieva S.M. Osteoporosis A Complication or Symptom of Axial Spondyloarthritis? // Amer. J. Med. Med. Sci. – 2023. – Vol. 13, №10. – P. 1550-1554.

9. Tashpulatova M.M., Kasimova M.B., Ziyayeva F.K. et al. Enhancement of the diagnosis and treatment of early rheumatoid arthritis // Int. J. Pharmac. Res. – 2020. – Vol. 12 (Issue 1). – P. 221-228.

10. Tashpulatova M.M., Nabiyeva D.A., Djuraeva E.R. et al. 14-3-3 (eta) protein as a new biomarker in rheumatoid arthritis // Int. J. Adv. Sci. Technol. – 2020. – Vol. 29, №5. – P. 1871-1877.

CHARACTERISTICAL TRAITS OF THE CLINIC AND DIAGNOSIS OF RHEUMATOID ARTHRITIS IN EARLY STAGES

Ziyayeva F.K., Djuraeva E.R., Ganieva N.A.

Objective: To study the clinical features and diagnostic significance of the 14-3-3η protein in the blood of patients in the early stages of the disease. **Material and methods:** The study included 68 patients with rheumatoid arthritis aged from 19 to 74 years (average age 44.2±3.2 years) with a disease duration of up to 1 year (from 6 to 52 weeks). **Results:** The onset of rheumatoid arthritis is observed mainly in middle age. Among the forms of arthritis, the leading one is polyarthritis with simultaneous damage to small and large joints. Patients at the early stage of rheumatoid arthritis were diagnosed with FC II articular insufficiency. At the early stage of RA, seronegativity was more pronounced. **Conclusions:** In patients with rheumatoid arthritis in the early stages, 14-3-3η protein in the blood is detected significantly more often than ACCP and rheumatoid factor, which indicates the high significance of this immunological method for the diagnosis of early rheumatoid arthritis.

Key words: early rheumatoid arthritis, articular syndrome, clinical picture, diagnosis, anticyclic citrulline peptide, protein 14-3-3η.